Source: PHARMAC
Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its upcoming meeting in March 2026.
Applications
Pertuzumab and trastuzumab for breast cancer
Adjuvant treatment for early breast cancer
The Committee will discuss an application for pertuzumab and trastuzumab to treat people with HER2-positive early breast cancer at high risk of recurrence. Pertuzumab and trastuzumab would be given to individuals after surgery (adjuvant treatment), together with chemotherapy. The Committee previously deferred making a recommendation for this application pending further evidence being published. Feedback and new evidence on this application was received during a consultation to fund this treatment for people with metastatic breast cancer.
Application for pertuzumab and trastuzumab (PHESGO)(external link)
Metastatic breast cancer
The Committee will consider feedback and new evidence received during consultation to widen access for people with HER2-positive metastatic or locally recurrent unresectable breast cancer in 2025.
Belzutifan for Von-Hippel Lindau disease
The Committee will discuss an application for belzutifan for the treatment of tumours associated with Von-Hippel Lindau disease (VHL). This application was reviewed by the Rare Disorders Advisory Committee who recommended CTAC also review the application. Pharmac is also seeking input from an expert experienced in treating VHL to inform this discussion.
Application for belzutifan (WELIREG)(external link)
Eltrombopag for aplastic anaemia
The Committee will discuss an application for eltrombopag for the treatment of severe aplastic anaemia. The treatment would be given as the first treatment for the condition, with immunosuppressive therapy.
Application for eltrombopag (Revolade)(external link)
Advisory meeting agenda setting
We have scheduled six CTAC meetings in 2026 to help increase capacity for cancer funding applications.
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.
